CLINICAL_TRIALS
trial_result
· 2020-02-25
Clinical Trial Update: Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment [Phase 4]
Summary
Phase 4 study updating on omalizumab in chronic spontaneous urticaria patients not responding to initial antihistamine treatment; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: CHRONIC SPONTANEOUS URTICARIA | Phase 4 | Status: COMPLETED | Results posted: 2020-02-25